Surrey Heartlands

Joint Formulary & PAD

Tirzepatide - Weight management in adults

You are here : Home > Formulary Search > Tirzepatide - Weight management in adults

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tirzepatide
Indication :
Weight management in adults
Group Name :
Keywords :
obesity, weight loss, overweight
Brand Names Include :
Mounjaro
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
6

Other Indications

Below are listed other indications that Tirzepatide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Weight management in adults.

Committee Recommendations (1)

05 Mar 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed tirzepatide for obesity and weight management in line with NICE TA1026.

A RED traffic light status has been agreed, and access will be through the specialist weight management service (SWMS) at Ashford & St Peters NHS Foundation Trust ONLY.

Tirzepatide will be added to the existing SWMS medical pathway alongside semaglutide and in line with the Guidance issued by the Society for Endocrinology and Obesity Management Collaborative UK.  Initially patients who meet the eligibility criteria listed in phase 1 of the guidance will be prioritised for referral to the specialist weight management service to allow those with the combination of highest and most urgent clinical need to be assessed ).

In line with NICE TA1026 further work is in progress around the establishment of our weight management programme, including establishing a service delivering care in the primary care setting.  A further paper will be considered by the Area Prescribing Committee in June or July 2025